MedTrace Logo

Relation Between NAFLD and BM DENSITY

NCT06038253 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-09-15

No results posted yet for this study

Summary

In general NAFLD is a common denominal for a broad spectrum of damage to the liver, which can be due to hepatocyte injury, inflammatory processes and fibrosis. This is normally seen on liver biopsy and can range from milder forms (steatosis) to the more severe forms (non-alcoholic steatohepatitis (NASH), advanced fibrosis, cirrhosis and liver failure). In these patients, advanced fibrosis is the major predictor of morbidity and liver-related mortality, and an accurate diagnosis of NASH and NAFLD is mandatory .

NAFLD is closely associated with metabolic disorders, including central obesity, dyslipidaemia, hypertension, hyperglycaemia and persistent abnormalities of liver function tests. NAFLD was shown to be connected with diseases that are usually not dependent on obesity, such as sarcopenia and osteoporosis

Target of the study :

1. Clarify predictive value of fibroscan and u/s in diagnosis of NAFLD.
2. Estimate the metabolic effect of NAFLD on bone density
3. Estimate the correlation between obesity , NAFLD and BMD

Conditions

Interventions

DEVICE

Fibroscan

Fibroscan is device to detect degree of liver fibrosis in NAFLD patients Dexa scan device detect degree of osteoporosis in NAFLD patients

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Ghada Abdelrahman alkhateeb, Professor · Assiut University

  • Ahmed Mohammed mostafa ashmawy, Assistant professor · Assiut University

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2026-10-01
Completion
2026-12-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06038253 on ClinicalTrials.gov